There is an error in the Correction published on November 15, 2018. In the last sentence of the caption for S2 Fig, “mdx” should be “C57BL6.” The publisher apologizes for the error. The correct sentence is: No difference was observed between treated and untreated C57BL6 mice.
Please view S2 Fig and the complete, correct S2 Fig caption below.
Supporting information
S2 Fig. Routine hematoxylin and eosin staining for examining muscle morphology.
Hematoxylin and eosin staining of TA tissue sections from treated C57BL6 mice with 2 µg PMO, 5 µg PNA and 5 µg 2′Ome PS by local injection at different time-points e.g. 48 hr, 2 and 4 weeks after injection, and C57BL6 normal controls. Scale Bar = 100 µm. No difference was observed between treated and untreated C57BL6 mice.
https://doi.org/10.1371/journal.pone.0212820.s001
(TIF)
References
- 1. Cao L, Han G, Gu B, Yin H (2014) Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy. PLoS ONE 9(11): e111079. https://doi.org/10.1371/journal.pone.0111079 pmid:25365558
- 2. Cao L, Han G, Gu B, Yin H (2018) Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy. PLoS ONE 13(11): e0207817. https://doi.org/10.1371/journal.pone.0207817 pmid:30440030
Citation: The PLOS ONE Staff (2019) Correction: Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy. PLoS ONE 14(2): e0212820. https://doi.org/10.1371/journal.pone.0212820
Published: February 20, 2019
Copyright: © 2019 The PLOS ONE Staff . This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.